Biogen Reports Results of Spinraza (nusinersen) in P-II NURTURE Study as a Foundation of Care in Spinal Muscular Atrophy

 Biogen Reports Results of Spinraza (nusinersen) in P-II NURTURE Study as a Foundation of Care in Spinal Muscular Atrophy

Biogen Reports Results of Spinraza (nusinersen) in P-II NURTURE Study as a Foundation of Care in Spinal Muscular Atrophy

Shots:

  • The P-II NURTURE study involves assessing of Spinraza in comparison to the natural history of the disease in 25 pre-symptomatic infants with SMA
  • The P-II NURTURE study resulted in achieving motor milestones including 100% of children sitting without support & 88% walking independently. The results support long-term safety & efficacy of Spinraza demonstrating continuous improvement in attaining motor milestones
  • Spinraza is a disease-modifying & an approved therapy for treating infants, children and adults with SMA, currently available in 40+ countries, being evaluated in a SHINE extension study of children with infantile and later-onset SMA as well the CS2/CS12 analysis of older patients

Click here to read full press release/ article | Ref: Biogen | Image: The Business Journals

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post